Keloid is characterized by benign overgrowth of dermal collagen in response to skin injury in genetically predisposed individuals. Intralesional triamcinolone and bleomycin have been used with varying success in the treatment of keloids. To compare the efficacy of intralesional triamcinolone versus intralesional bleomycin in the treatment keloids. A total of 164 patients were randomized into two of 82 each. Group A received intralesional bleomycine and Group B received intralesional triamcinolone. Patients were scored at baseline and at the end of treatment for therapeutic response based on reduction on patient and observer scar assessment scale (POSAS). Mean baseline POSAS score was 91 ± 10.98 SD check in Group A and 90 ± 10.85 SD in Group B. POSAS score after 24 weeks 26 SD ± 11.91 in Group and 34 ± 12.28 in Group B. This difference was statistically difference. Intralesional bleomycin is more efficacious than intralesional triamcinolone acetonide in the treatment of keloids.

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13036DOI Listing

Publication Analysis

Top Keywords

intralesional triamcinolone
20
treatment keloids
16
intralesional bleomycin
12
intralesional
9
efficacy intralesional
8
versus intralesional
8
triamcinolone acetonide
8
acetonide treatment
8
group received
8
received intralesional
8

Similar Publications

Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review.

Arch Dermatol Res

January 2025

Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA.

The use of immunotherapy is an emerging treatment option for advanced malignancies. Cutaneous adverse events following cancer immunotherapy are well-documented in the literature. The rarer cutaneous adverse effects are less characterized, including eruptive keratoacanthomas (KA).

View Article and Find Full Text PDF

Cutaneous pseudolymphoma successfully treated with intralesional triamcinolone acetonide: A case report.

SAGE Open Med Case Rep

January 2025

Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Cutaneous pseudolymphoma refers to a group of skin conditions that simulate lymphoma either clinically and/or histologically. Cutaneous pseudolymphoma is a benign disorder that can often be misdiagnosed and has a wide range of treatment modalities. Currently, there is no gold standard of treatment, and the literature would benefit from more reports on successful and unsuccessful treatments of cutaneous pseudolymphoma.

View Article and Find Full Text PDF

Background: Treatment of hypertrophic burn scars is challenging. Intralesional injection of corticosteroids has been the first line of treatment. Triamcinolone Acetonide (TA) and Bleomycin (BLE) are standard therapeutic options.

View Article and Find Full Text PDF

Introduction: Conservative treatment options, such as rest, massage, cold and heat packs, wrist splints, braces, physical therapy, thumb spica casts, and local steroid injections, have been used with mixed results to treat De Quervain's tenosynovitis. Surgical treatment, like releasing the first dorsal wrist compartment, is the last resort for resistant cases of De Quervain's tenosynovitis, exhibiting an efficacy of 91%. However, complications and increased expenses have limited the use of surgical interventions.

View Article and Find Full Text PDF
Article Synopsis
  • Soft tissue filler injections, popular for cosmetic procedures, can lead to adverse reactions, particularly augmentation rhinoplasty in Asian countries due to low nasal bridges.
  • There is a need for effective treatments for such reactions, as the complications can severely impact a patient's quality of life.
  • A study found that a combination of specific medications resulted in successful treatment of swelling and deformity in two patients, with no side effects after the regimen.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!